Q-omics provides the consensus-scored PRKCSH profile across patient tissues and cancer cell-line models. PRKCSH expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, PRKCSH is differentially expressed in 16, with the highest sampling consensus in HNSC. Additionally, PRKCSH protein abundance shows 24,391 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KICH, HNSC, and GBM as cancer lineages where PRKCSH shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PRKCSH — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PRKCSH survival associations across molecular data types. PRKCSH RNA expression shows survival associations in the most cancer types (23), followed by mutation status (5) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PRKCSH RNA expression–survival associations across cancer types. High PRKCSH expression shows unfavorable associations in KICH, ACC, KIRP, MESO and LGG, but favorable associations in UVM. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify KICH as the clearest survival context for PRKCSH RNA expression.
This table summarizes PRKCSH tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 7. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for PRKCSH. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PRKCSH shows higher tumor expression in HNSC, KIRC, KIRP, STAD, BLCA and COAD. The HNSC box plot shows higher PRKCSH RNA expression in tumor versus normal tissue (log2 FC = +1.093, t-test p < 0.001).
This table shows molecular features associated with PRKCSH in patient tissues and cancer cell lines. In patient samples, PRKCSH shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, PRKCSH RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in SKIN and LARGE_INTESTINE.
